Palisade Bio

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share.

Palisade Bio Announces $2.0 Million Registered Direct Offering

NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study

Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022

Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements

Live moderated video webcast discussion among members of Management and a renowned Key Opinion Leader on Tuesday, May 3rd at 10:00 AM ET Live moderated video webcast discussion among members of Management and a renowned Key Opinion Leader on Tuesday, May 3rd at 10:00 AM ET

Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event

CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that of Palisade Bio, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28–30, 2022.

Palisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted by M-Vest

Draganfly Inc

Enservco

Smart for Life Inc

SuperCom

We're seeing a lot of activity from penny stocks today and have put together a list of the top ones for investors to watch. The post Top Penny Stocks Today: Why DPRO, PALI, ENSV, SPCB and SMFL Are Up Today appeared first on InvestorPlace.

Top Penny Stocks Today: Why DPRO, PALI, ENSV, SPCB and SMFL Are Up Today

Palisade Bio Inc (NASDAQ: PALI) has received a "Study May Proceed" letter from the FDA for a Phase 3 trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery. The trial will enroll approximately 600 subjects.

FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study

Troika Media Group

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for March 22nd, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 22nd, 2022

CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced that the Company received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery.

Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery

CARLSBAD, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients suffering with acute and chronic gastrointestinal (GI) complications, today provides a business update and reports its financial results for the year ended December 31, 2021.

Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update

Palisade Bio Inc (NASDAQ: PALI) announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN), highlighting LB1148 reduced incidence of adhesions by 72% in patients undergoing bowel resection. Studies assessed the efficacy of LB1148 to reduce the.

Palisade Bio's LB1148 Cuts The Risk of Adhesion Formation By 72% After Bowel Resection Surgery

Data from Pooled-Analysis of Enteral Protease Inhibitor LB1148 Demonstrated 72% Reduction in the Risk of Adhesion Formation in Patients Undergoing Bowel Resection Surgery

Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

Dallas, Texas--(Newsfile Corp. - March 14, 2022) - Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions. The virtual presentation will review the Company's data being presented at the SAGES 2022 Annual Meeting and the need for new pharmaceutical options to prevent post-surgical...

Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners

Company to Present Adhesions Prevention Data on Wednesday, March 16, 2022, at 8:30 a.m. ET Company to Present Adhesions Prevention Data on Wednesday, March 16, 2022, at 8:30 a.m. ET

Palisade Bio (Nasdaq: PALI) to Present New Clinical Data of LB1148 for Preventing Adhesions in Conjunction with Next Big Thing Session at Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting

CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, will present at the Biocom Global Life Science Partnering Conference in San Diego on Thursday, February 24, 2022. Palisade Bio's Chief Executive Officer, Tom Hallam, Ph.D., is scheduled to present an updated presentation at 11:30 a.m. Pacific Time. Palisade Bio's presentation can be accessed at on our website at www.palisadebio.com/investors.

Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference

Expands Clinical Operations Team in Advance of Pivotal Clinical Studies Expands Clinical Operations Team in Advance of Pivotal Clinical Studies

Palisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae to Leadership Team

Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148 Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148

Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

Vinco Ventures

Express

Farmmi

Senseonics Holdings

Here are 5 penny stocks to watch this week The post Best Penny Stocks To Buy This Week? 5 Names You Should Know Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy This Week? 5 Names You Should Know Now

Context Therapeutics LLC

Flotek Industries

Are these on your list of the best penny stocks to buy right now? Here's what analysts think The post 4 Penny Stocks To Buy Now According To Analysts, Targets Over 300% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy Now According To Analysts, Targets Over 300%

CARLSBAD, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022. The Palisade Bio management team also will be hosting investor meetings during that period and talking about their lead program, LB1148. LB1148 has shown significant results in a Phase 2 trial with a 1.1-day improvement in return to bowel function following GI surgery in the mean.

Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase

Issuance of Additional U.S. Patent No11,202,768 Further Bolsters Palisade Bio's Patent Portfolio

Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus

EPO expected to publish patent on December 22, 2021 EPO expected to publish patent on December 22, 2021

Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035

CARLSBAD, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications (the “Company”), today announced that it had made equity grants to three new employees under its 2021 Inducement Plan (the “Plan”).

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations

CARLSBAD, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies that help patients with acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the third quarter ended September 30, 2021.

Palisade Bio Reports Third Quarter Financial Results

Palisade Bio is developing oral therapies targeting protease inhibition in GI diseases. The Company's lead candidate LB1148 showed promising data in Phase 2 trials.

News for Palisade Bio Stock (PALI)